journal article·2017-11-01

Prediction of drug-binding sites in HCV NS5B polymerase: MD simulation study

Gargi Tiwari, Vishnudatt Pandey, Rajendra Prasad Ojha

Emerging Materials Research· Volume 6· Issue 2
Publisher page

Abstract

Hepatitis C virus (HCV) is a small, single-stranded, positive-sense ribonucleic acid (RNA) virus and is a member of the Flaviviridae family of viruses. Its genome has a length of 9.6 kb and encoding a polyprotein of about 3000 amino acids which is cleaved co- and post-translationally by cellular and viral proteases into 10 different products: core, envelope protein E1, E2, p7, nonstructural proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B. Core, E1 and E2 are the main viral constituents of the HCV particle. NS5B of the hepatitis C virus, a RNA-dependent RNA polymerase, is an important therapeutic target. In order to gain deeper insight into and to know its molecular mechanism, the authors employed molecular dynamics simulation at the nanosecond scale. Initial coordinates were taken from the protein data bank entries with IDs 3IGV and 3GYN. The present study shows the strong binding affinity of the inhibitor with NS5B polymerase. The binding free energies, calculated by the molecular mechanics and Poisson–Boltzmann surface area/generalized Born surface area method, suggest a good connection with the experimental biological activity. The analysis of the combined simulation results has identified that Tyr448, Ser556 and Asp318 are the key amino acid residues in NS5B binding. The results obtained from this study provide some insights into the development of novel strong NS5B inhibitors.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Hepatitis C virus research · Hepatitis B Virus Studies · HIV Research and Treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Physics, Deen Dayal Upadhyaya Gorakhpur University, Gorakhpur, India

References (33)

Show source-provided references
1. Houghton M · 1996 · 1035
2. Lemon SM · 1995 · 1474
3. Purcell RH · 1994 · 569
4. 10.1016/S0065-3527(04)63002-810.1016/S0065-3527(04)63002-8 ↗
5. 10.1038/nrmicro164510.1038/nrmicro1645 ↗
6. 10.1038/nrd405010.1038/nrd4050 ↗
7. 10.1016/S0969-2126(00)80031-310.1016/S0969-2126(00)80031-3 ↗
8. 10.1021/bi400251g10.1021/bi400251g ↗
9. Delang L · Current Topics in Microbiology and Immunology · 2013 · 369 · 289
10. 10.1146/annurev-pharmtox-011112-14025410.1146/annurev-pharmtox-011112-140254 ↗
11. Ng KK · Current Topics in Microbiology and Immunology · 2008 · 320 · 137
12. 10.1074/jbc.M80149020010.1074/jbc.M801490200 ↗
13. Kim WR · Hepatology · 2002 · 36 · 3010.1002/hep.1840360705 ↗
14. 10.1056/NEJM19990819341080210.1056/NEJM199908193410802 ↗
15. 10.1016/S0168-8278(99)80369-910.1016/S0168-8278(99)80369-9 ↗
16. 10.1126/science.177.4050.70510.1126/science.177.4050.705 ↗
17. Schroder C · Journal of Basic Microbiology · 1982 · 22 · 15210.1002/jobm.19820220219 ↗
18. 10.1016/S0065-3527(08)60082-210.1016/S0065-3527(08)60082-2 ↗
19. 10.1126/science.277.5325.57010.1126/science.277.5325.570 ↗
20. 10.1016/j.bmcl.2009.09.05110.1016/j.bmcl.2009.09.051 ↗
21. 10.1016/j.bmcl.2008.11.04810.1016/j.bmcl.2008.11.048 ↗
22. 10.1126/science.109636110.1126/science.1096361 ↗
23. 10.1007/s00894-009-0519-910.1007/s00894-009-0519-9 ↗
24. 10.1006/jmbi.2000.405710.1006/jmbi.2000.4057 ↗
25. 10.1016/0010-4655(95)00041-D10.1016/0010-4655(95)00041-D ↗
26. 10.1002/jcc.1034910.1002/jcc.10349 ↗
27. 10.1002/jcc.1012810.1002/jcc.10128 ↗
28. 10.1002/jcc.2003510.1002/jcc.20035 ↗
29. 10.2174/1573409911309666003610.2174/15734099113096660036 ↗
30. 10.1371/journal.pone.004284610.1371/journal.pone.0042846 ↗
31. 10.1021/jm010027910.1021/jm0100279 ↗
32. Case D
33. 10.1016/j.jmgm.2013.10.00510.1016/j.jmgm.2013.10.005 ↗